CureVac Overview

  • Founded
  • 2000
Founded
  • Status
  • Public
  • Employees
  • 554
Employees
  • Stock Symbol
  • CVAC
Stock Symbol
  • Share Price
  • $94.30
  • (As of Friday Closing)

CureVac General Information

Description

CureVac NV a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. The company's product portfolio includes clinical and pre-clinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. Its clinical programs are CV8102, which it is evaluating in a Phase 1 clinical trial for the treatment of four types of solid tumors, and CV7202, which it is investigating in a Phase 1 clinical trial for potential vaccination against rabies. It is also rapidly advancing its mRNA vaccine program against coronavirus SARS- CoV-2), for which the company initiated a Phase 1 clinical trial.

Contact Information

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • Friedrich-Miescher-Strabe 15
  • 72076 Tübingen
  • Germany
+49 07071 00000

CureVac Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

CureVac Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$94.30 $92.97 $36.15 - $151.80 $17.6B 187M 796K -$0.67

CureVac Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 8,344,634
Revenue 55,569 19,496 15,189
EBITDA (103,363) (81,475)
Net Income (119,727) (111,802) (84,069)
Total Assets 1,199,773 146,317 143,742
Total Debt 35,979 88,659 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CureVac Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CureVac‘s full profile, request access.

Request a free trial

CureVac Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
CureVac NV a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messe
Drug Discovery
Tübingen, Germany
554 As of 2020
00.000
00000000 00.000

0000000

voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000 000000000
Cambridge, MA
0000 As of 0000
00.00
00000000000 00.00

00000000

e cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cu
0000000000000
Norcross, GA
0 As of 0000
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CureVac Competitors (40)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Moderna Therapeutics Formerly VC-backed Cambridge, MA 0000 00.00 00000000000 00.00
00000000 000000000 Corporation Norcross, GA 0 000000000000
000000 00000000 Venture Capital-Backed Williamsville, NY 00 00.000 000000000 - 00.000
00000000 Formerly VC-backed Mainz, Germany 0000 00.000 00000000 00.000
000000000 Formerly PE-Backed Freiburg, Germany 000000&0
You’re viewing 5 of 40 competitors. Get the full list »

CureVac Executive Team (20)

Name Title Board Seat Contact Info
Franz-Werner Haas Ph.D Chief Executive Officer & Chief Operating Officer, Operations
Pierre Kemula Chief Financial Officer, Finance
Mariola Fotin-Mleczek Ph.D Chief Technology Officer, Technology
Igor Splawski Chief Scientific Officer
Antony Blanc Ph.D Chief Business Officer & Chief Commercial Officer
You’re viewing 5 of 20 executive team members. Get the full list »

CureVac Board Members (9)

Name Representing Role Since
Christof Hettich Ph.D dievini Board Member 000 0000
Craig Tooman CureVac Board Member 000 0000
Friedrich Von Bohlen Ph.D Self Managing Director & Board Member 000 0000
Ingmar Hoerr Ph.D CureVac Board Member 000 0000
Jean Stéphenne CureVac Chairman 000 0000
You’re viewing 5 of 9 board members. Get the full list »

CureVac Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CureVac Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CureVac‘s full profile, request access.

Request a free trial